Can eye drops be used to treat diabetic retinopathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Eye Drops for Diabetic Retinopathy

Eye drops are not part of standard treatment for diabetic retinopathy according to current clinical guidelines, which recommend intravitreal anti-VEGF injections, laser photocoagulation, and systemic metabolic control as the established therapeutic approaches. 1, 2

Guideline-Based Standard Treatment

The American Academy of Ophthalmology and International Council of Ophthalmology clearly outline that management of diabetic retinopathy centers on: 1, 2

  • Intravitreal anti-VEGF agents (ranibizumab, aflibercept, bevacizumab) for proliferative diabetic retinopathy and diabetic macular edema 2
  • Laser photocoagulation (panretinal photocoagulation for proliferative disease; focal/grid laser for macular edema) 1, 2
  • Intravitreal corticosteroids as an alternative treatment option 1
  • Systemic metabolic control including hemoglobin A1c <7.0%, blood pressure management, and lipid control 1, 2

These guidelines make no mention of topical eye drops as a therapeutic modality for diabetic retinopathy. 1, 2

Emerging Research on Topical Eye Drops

While not yet guideline-endorsed, several investigational topical agents show promise in preclinical and early clinical studies:

Corticosteroid Eye Drops

  • Limited evidence suggests benefit in diabetic macular edema, with four studies reporting favorable effects and one showing positive trends 3
  • However, this remains investigational and not part of standard practice 3

Neuroprotective Agents

GLP-1 eye drops demonstrated protective effects in experimental diabetes by: 4

  • Facilitating presynaptic GABA release to retinal ganglion cells 4
  • Improving visual acuity and contrast sensitivity in diabetic rats 4
  • Enhancing retinal ganglion cell survival through activation of the PI-PLC/IP3R/Ca2+/PKC signaling pathway 4

Sitagliptin (DPP-4 inhibitor) eye drops prevented retinal neurovascular unit dysfunction in non-diabetic rat models by: 5

  • Reducing inflammatory factors and oxidative markers 5
  • Preventing glial activation and acellular capillary formation 5
  • Maintaining retinal thickness and vascular integrity 5

PEDF peptide eye drops reduced multiple pathological features in diabetic mice: 6

  • Decreased vascular leakage by ~60% 6
  • Reduced 9/20 inflammatory cytokines including IFN-γ, IL-6, and TNF-α 6
  • Prevented microglia activation by ~60% and retinal ganglion cell death by ~22% 6

Minocycline hydrochloride eye drops (1 mg/ml) showed safety and efficacy in diabetic rats by: 7

  • Preserving retinal thickness and ganglion cell layer integrity 7
  • Maintaining better electroretinography responses compared to untreated controls 7
  • Protecting blood-retinal barrier function 7

NSAIDs Eye Drops

  • Reported favorable effects in diabetic macular edema, but not effective in non-center involving disease 3
  • Evidence remains limited and heterogeneous 3

Critical Limitations and Clinical Reality

A systematic review of topical treatments for diabetic retinopathy found significant heterogeneity in study designs, patient populations, and outcome measures, making definitive conclusions impossible. 3 The review identified only seven randomized trials among 19 total studies examining 11 different pharmacological drug classes. 3

Key Caveats:

  • All promising eye drop studies are preclinical (animal models) or very early-phase human trials 4, 5, 6, 7
  • No topical eye drop formulation has FDA approval or guideline endorsement for diabetic retinopathy treatment 1, 2
  • Intraocular drug delivery via eye drops faces significant barriers including corneal penetration, achieving therapeutic vitreoretinal concentrations, and maintaining sustained drug levels 6
  • The evidence base is insufficient for clinical decision-making regarding which patients might benefit, optimal dosing, or long-term safety 3

Clinical Algorithm for Current Practice

For any patient with diabetic retinopathy, follow this approach:

  1. Optimize systemic control first: Achieve HbA1c <7.0%, normalize blood pressure, and manage dyslipidemia 1, 2

  2. Determine disease severity and refer appropriately: 2

    • No/mild nonproliferative DR without macular edema: Re-examine in 1-2 years 2
    • Moderate nonproliferative DR: Refer to ophthalmologist, follow-up every 3-6 months 2
    • Severe nonproliferative DR: Urgent ophthalmology referral, follow-up <3 months 2
    • Proliferative DR: Urgent referral within 1 month for laser or anti-VEGF treatment 2
    • Center-involving macular edema: Urgent referral within 1 month for intravitreal anti-VEGF therapy 2

  3. Implement proven treatments under ophthalmology care: 1, 2

    • Intravitreal anti-VEGF injections for proliferative disease and macular edema 2
    • Panretinal photocoagulation for high-risk proliferative retinopathy 2
    • Consider intravitreal corticosteroids as alternative therapy 1

Do not substitute or delay proven intravitreal treatments with investigational eye drops. The morbidity and mortality implications of vision loss from untreated diabetic retinopathy are too significant to rely on unproven topical therapies. 1, 2

References

Related Questions

Why does vision remain relatively good after pan‑retinal photocoagulation for diabetic retinopathy, and what causes the persistent floaters?
In a 72-year-old diabetic patient with a foot contusion, soft tissue swelling, lateral third- and fourth-metatarsal tenderness, inability to bear weight but preserved flexion, extension, and external rotation, what is the appropriate management, including weight-bearing restrictions, analgesic regimen, and need for podiatry referral to evaluate peripheral neuropathy?
For a patient now in the prediabetes range, is yearly retinal screening and podiatry review necessary?
A 28-year-old newly diagnosed with diabetes presents with visual disturbance 12 days after starting treatment, and fundus examination shows no diabetic retinopathy; what is the likely cause and recommended management?
What are the etiologies and management strategies for toe necrosis in an adult (middle‑aged or older) patient with risk factors such as diabetes mellitus, smoking, peripheral arterial disease, chronic venous insufficiency, or prior foot trauma?
In a patient who developed a transient ischemic attack after a clot evacuation procedure and has hematuria, how should dual antiplatelet therapy be initiated?
What is the Yasui procedure?
What is the recommended intramuscular dosing of ziprasidone (Geodon)?
What bolus dose of furosemide (Bumex) should be given before increasing the continuous infusion from 1 mg/hr to 1.5 mg/hr?
Can you provide a tapering protocol for pantoprazole (Pantoloc) 40 mg orally once daily?
What is the differential diagnosis for a patient with limited active and passive shoulder range of motion, difficulty and pain lifting the arm overhead, and positive Empty‑Can, Speed’s, Hawkins‑Kennedy, and O’Brien tests?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.